Q3 2024 Regenxbio Inc Earnings Call Transcript
Key Points
- Regenxbio Inc (RGNX) is making significant progress in advancing its late-stage programs, including RGX 202 for Duchenne and RGX 121 for Hunter syndrome.
- The company has initiated the BLA filing for RGX 121, which could become the first gene therapy for Hunter syndrome, marking a major milestone.
- RGX 202 is positioned as a potential best-in-class gene therapy for Duchenne, with promising clinical data and a favorable safety profile.
- Regenxbio Inc (RGNX) has a strong cash position, with $279 million in cash and equivalents, expected to fund operations into 2026.
- The company is collaborating with AbbVie on RGX 314, with plans to initiate a global pivotal trial for diabetic retinopathy in the first half of 2025.
- Regenxbio Inc (RGNX) faces uncertainties and risks associated with forward-looking statements and regulatory approvals.
- The company experienced a decrease in cash and equivalents from $314 million at the end of 2023 to $279 million as of September 30, 2024.
- There is concern about the small sample size for RGX 202, which may impact the interpretation of functional data.
- The potential impact of biosimilars on the market for RGX 314 in wet AMD remains uncertain.
- Regenxbio Inc (RGNX) is preparing for a potential Adcom for RGX 121, which could delay the approval process.
Welcome everyone to the Q3 2024 Regenxbio Earnings conference call. At this time, all participants are on a listen-only mode. After the speaker presentation, there will be a question and answer session to ask a question. During the session. You will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised to withdraw your question. Please press star 11 again. Please be advised that today's conference is being recorded at this time. I'd like to turn the conference over to Patrick Christmas, Chief Legal Officer of Regenxbio. Please go ahead.
Good afternoon and thank you for joining us today. Earlier this afternoon, Regenxbio released financial and operating results for the third quarter ended September 30th 2024. The press release is available on our website at www.regenxbio.com. Today's conference call will include forward-looking statements regarding our financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
